Back to articles

Metastatic Colon Cancer: Exciting Developments, but Costs High


The first agents to show real progress in treating metastatic colon cancer reached the U.S. market earlier this year, and their availability offers the hope of a few extra months of life for patients with this condition. However, that progress comes at a high economic cost that has many questioning how far society can go in these types of clinical situations.


Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.

Erlichman C, Sargent DJ. New treatment options for colorectal cancer [editorial]. N Engl J Med. 2004;351:391–2.

Schrag D. The price tag on progress—chemotherapy for colorectal cancer [perspective]. N Engl J Med. 2004;351:317–9.